Skip to main content

Table 2 Baseline clinical characteristics of participants

From: Effect of switching basal insulin regimen to degludec on quality of life in Japanese patients with type 1 and type 2 diabetes mellitus

Items Type 1 Type 2
Number (male/female) 10 (5/5) 20 (11/9)
Age (years) 52.1 ± 15.3 61.9 ± 13.1
BMI (kg/m2) 22.2 ± 2.7 24.7 ± 4.8
Duration of diabetes (years) 7.5 ± 4.2 14.6 ± 7.6
HbA1c (%) 8.2 ± 1.4 7.6 ± 1.2
Prior treatment insulin  
Insulin glargine 8 (80 %) 13 (65 %)
Insulin detemir 2 (20 %) 7 (35 %)
Bolus insulin 10 (100 %) 7 (35 %)
The frequency of injections with basal insulin before switching
Once 3 (30 %) 13 (65 %)
Twice 7 (70 %) 7 (35 %)
Other concomitant drugs  
Glucagon like peptide-1 receptor agonist 0 (0 %) 0 (0 %)
Sulphonylurea 0 (0 %) 2 (10 %)
Glinide 0 (0 %) 7 (35 %)
Metformin 0 (0 %) 10 (50 %)
Pioglitazone 0 (0 %) 2 (10 %)
α-glucosidase inhibitor 0 (0 %) 5 (25 %)
Dipeptidyl peptidase 4 inhibitor 0 (0 %) 8 (40 %)
Sodium glucose cotransporter 2 inhibitor 0 (0 %) 0 (0 %)